Oncternal Therapeutics Inc (ONCT)

[PJO]

GTx Meets Primary Efficacy Endpoint In Phase 2 Study On Breast Cancer Drug

07:46 AM EST, 12/08/2016 (MT Newswires) -- GTx (GTXI), a biopharmaceutical company, said it met its primary efficacy endpoint in an ongoing phase 2 trial of enobosarm in breast cancer patients.

The company said the study evaluated women with advanced, estrogen receptor positive androgen receptor positive breast cancer. In the 9 mg cohort a total of 9 of 22 patients achieved a clinical benefit response at 24 weeks, with two patients seeing a partial response and seven with stable disease at 24 weeks.

Enobosarm 9 mg appears to be safe and generally well tolerated, the company said. The independent safety monitoring committee met on Dec. 1 and recommended the trial continue as planned. The company plans to report top-line clinical results following completion of the trial, which is anticipated in mid-2017.